top of page

Together We Can Improve
Chronic Kidney Disease

Patient Outcomes Nationwide

The Facts

As many as 9 in 10 adults with chronic kidney disease (CKD) do not know they have it.
Early CKD has no signs or symptoms until it becomes severe.



Diabetes and hypertension are the leading causes of kidney failure in the United States, accounting for 3 out of 4 cases. 

The interdependent relationship between heart disease, kidney disease, and metabolic disease (diabetes) defines cardio-renal-metabolic (CRM) disease. When one of these systems is negatively affected, it exerts negative effects on the other two.


CKD cost of care is steep. Medicare spends more than $85.4 billion annually on CKD and $50.8 billion on end-stage renal disease (ESRD).


The Care Gap

Despite guideline recommendations, proper testing for CKD in US adults with diabetes and hypertension—which is also a HEDIS (Healthcare Effectiveness Data and Information Set) measurement—is only done about 20% of the time in routine clinical care.


The Solution

Scalable behavior change that improves patient outcomes requires an integrated approach in today’s fragmented US healthcare system.  

So QC-Health, Inc (a provider-focused benefit corp), Aventria Health Group (a secondary-provider-focused agency working with pharma, biotech, and medical devices), and Relentless Health Value podcast (focused on healthcare influencers) began collaborating to impact CKD outcomes.

Groundswell Movement logo_V2.1.png

We started a

A Groundswell Movement is a series of collaborations with healthcare stakeholders to change behavior in the way chronic disease patient populations are identified and treated. How? By engaging providers and patients with evidence-based knowledge and a digital care plan solution in the clinical workflow and tracking the measurable impact on patient outcomes and costs.

Come Join the CKD Groundswell Movement

Providers and payers: Find out about our free CKD digital care plan solution you can use to get patients with diabetes and/or hypertension diagnosed and staged using evidence-based guidelines.

Life sciences/CKD cost-containment solutions/Other for-profit companies: Consider sponsoring our work and discussing other ways to collaborate.

Healthcare consultants and others: Join us in helping the healthcare industry level up CKD care.


References: 1. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. Accessed August 29, 2023. 2. Centers for Disease Control and Prevention. Chronic Kidney Disease Basics. Accessed August 29, 2023. 3. Kadowaki T, Maegawa H, Watada H, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24(12):2283-2296. 4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Healthcare Expenditures for Persons With CKD. Accessed August 29, 2023.,(Tables%206.1%20and%206.2) 5. Alfego D, Ennis J, Gillespie B, et al. Chronic kidney disease testing among at-risk adults in the US remains low: real-world evidence from a national laboratory database. Diabetes Care. 2021;44(9):2025-2032.

bottom of page